CJC-1295 with DAC

Human evidence can mean a controlled clinical study, an observational study, a safety or exposure report, or evidence from a particular finished formulation. Those are different kinds of information.

Limited human evidence. Some human evidence exists, but it is small, early, indirect, or limited to a particular formulation or population.

Preclinical means research in cells, tissues, or animals rather than in people. It can help researchers form a hypothesis, but it cannot establish a human benefit or a complete human safety profile.

Rat and laboratory studies examined albumin binding and prolonged hormone-axis stimulation of the DAC molecule. They do not establish clinical outcomes or long-term safety in people.[3]

Preclinical findings do not establish outcomes in people.

Risk information may describe the compound, a finished product, a route, a population, or product-quality concerns. The cited material does not replace a current product label or an individual professional assessment.

This section is about the United States only. Status applies to a product, formulation, route, population, and use—not to a name in the abstract. A status shown here is not a recommendation or a statement about another country.

• Source/status dateJul 22, 2026

  Research only

  CJC-1295 with DAC is not FDA approved. FDA found the evidence insufficient to support inclusion of CJC-1295-related substances on the 503A bulks list.

  Specific product form or route is not separately published in this status record.

  Open source context

The date above is the date attached to the published status record or source context. It is not necessarily the original approval date.

These prompts help organise a conversation with a qualified professional. They do not create a treatment recommendation, dose, or protocol.

• EvidenceWhich human evidence applies to the exact product, form, route, and use being discussed?
• What remains uncertainWhat is known, and what remains uncertain for this specific context?
• RisksWhich important warnings, common effects, and product-quality concerns should be discussed?
• U.S. statusWhat does the U.S. status cover, and what does it not cover?

Related means that the profiles share a topic, pathway, product context, or research question. It does not mean that they are equivalent.

• CJC-1295 without DACThe DAC modification changes albumin binding and evidence for one form cannot be transferred to the other.

PeptideGrid review date: Jul 22, 2026. Sources support the specific sections that cite them. Publication does not imply endorsement, equivalence, or individual suitability.

1. 1

   FDA briefing document for CJC-1295-related substances

   U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee briefing document: CJC-1295-related substances. 2024.

   U.S. Food and Drug Administration · Published Oct 29, 2024 · Accessed Jul 22, 2026 · Regulatory source

   Open source
2. 2

   Human pharmacodynamic studies of CJC-1295 with DAC

   Teichman SL, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805.

   PubMed-indexed primary study · Published Mar 1, 2006 · Accessed Jul 22, 2026 · Clinical study

   Open source
3. 3

   Albumin-binding preclinical study of CJC-1295 with DAC

   Jette L, et al. Human growth hormone-releasing factor with a prolonged half-life stimulates growth hormone and insulin-like growth factor I secretion in rats. Endocrinology. 2005;146(7):3052-3058.

   PubMed-indexed primary study · Published Jul 1, 2005 · Accessed Jul 22, 2026 · Preclinical study

   Open source